Drugs News and Research

RSS

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

Combined therapy for acute leukemia shows promising results

Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.

25 Aug 2009

LAF report estimates the total economic burden of new cancer cases at $305 billion in 2009

A landmark report released today by the Lance Armstrong Foundation (LAF) estimates the total economic burden of new cancer cases at $305 billion in 2009. The findings are included in the report, "Breakaway: The Global Burden of Cancer - Challenges and Opportunities," released today in Dublin at the premiere LIVESTRONG Global Cancer Summit.

25 Aug 2009

New RAND study finds that Prescription Benefit Program for Medicare recipients surpasses expectations

The program created to provide Medicare recipients with prescription drug benefits exceeded expectations during its first two years, extending pharmacy coverage to most seniors while reducing their overall spending on drugs, according to a new RAND Corporation study.

25 Aug 2009

Value-Based Insurance Design improves health care services

As members of Congress continue to debate proposals for health care reform, the National Pharmaceutical Council (NPC) has released a new report on an important approach being used by leading edge employers for improving patient health outcomes - Value-Based Insurance Design (VBID).

25 Aug 2009

Impact Fusion International to commence filming of Anti-Steroids and Anti-Drug Campaign

Impact Fusion International, Inc. (PINKSHEETS: IFUS) announced that it will begin filming of its Anti-Steroids and Anti-Drug Campaign with retired NFL star Kenneth Davidson. This campaign will be centered around the Intact Sports Nutrition products Intact Endurance and Intact Protein+ that will be sold as a system called Intact Complete.

25 Aug 2009

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg.

25 Aug 2009

Myoderm expands its portfolio to include drug procurement, management and distribution services

Myoderm, a leading global pharmaceutical supplier of comparator drugs for clinical research and clinical trials, has expanded its portfolio to include Distribution Management Services. This new capability provides their clients with an efficient solution for sourcing, managing, and distributing off-the-shelf, commercial drugs used in clinical trials.

25 Aug 2009

Comparative effectiveness: Back surgery remains popular despite poor study results

Studies have recently found that vertebroplasty - a type of back surgery in which cement is injected into the spine - isn't effective, but many patients and their doctors insist it works.

25 Aug 2009

Scientists cultivate multiple types of retina cells from human stem cells

A team of scientists from the University of Wisconsin-Madison School of Medicine and Public Health has successfully grown multiple types of retina cells from two types of stem cells — suggesting a future in which damaged retinas could be repaired by cells grown from the patient's own skin.

25 Aug 2009

UCLA finds link between high cholesterol and osteoporosis

A new UCLA study sheds light on the link between high cholesterol and osteoporosis and identifies a new way that the body's immune cells play a role in bone loss

25 Aug 2009

Thick blood to cause or prevent strokes and heart attacks proved by scientists

"Thick" blood can cause heart attack and stroke, but also prevent them. Scientists at Heidelberg University Hospital have explained the mechanism of this clinical paradox for the first time on an animal model. Mice with a greater tendency to form blood clots have larger plaques in their vessels, but they are more stable.

24 Aug 2009

Washington post examines spread of drug-resistant TB in Russia

The Washington Post examines the spread of drug-resistant tuberculosis in Russia where "[p]reliminary surveys have recorded an uptick in infections," which could be the "start of a surge fueled by declining living standards and deteriorating medical care resulting from the country's worst economic slowdown in a decade," experts say.

24 Aug 2009

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

24 Aug 2009

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it will sponsor a clinical study comparing the effects of ActiPatch® Therapy to Tylenol® for the treatment of muscle pain and soreness.

24 Aug 2009

ARIAD's petition for rehearing the Lilly NF-Kb patent lawsuit is granted by the Federal Circuit

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and its co-plaintiffs today announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) has granted their petition for rehearing en banc and has vacated its April 2009 decision in the appeal that Eli Lilly and Co. filed in 2008. All twelve judges of the Federal Circuit will now rehear and reassess the merits of Lilly’s appeal.

24 Aug 2009

Simcere to collaborate with Sun Yat-Sen University Cancer Center to research and develop anti-cancer drugs

Located in Guangzhou, Sun Yat-Sen University Cancer Center is one of China's renowned cancer research institutions, prominent in pre-clinical and clinical oncology research. The Sun Yat-Sen University Cancer Center was established to research anti-cancer treatments with a specific focus on developing major innovative drugs.

24 Aug 2009

Study reveals that increased neurostimulation market offers growth for device industries

The device industry would do well to focus on the treatment needs of individuals suffering from nerve-related disorders as implanted technologies that deliver electrical stimulation begin to supplant drugs for treating certain nerve-related disorders.

24 Aug 2009

PLoS Medicine's editors to eventually stamp ghostwriting

Today, PLoS Medicine places in the public domain all documents - around 1500 - released after the journal and The New York Times intervention in the Prempro case. The documents, are available on the PLoS Medicine website, and are uploaded in the form that PLoS received them from the court.

24 Aug 2009

Gross profit declines for China Nepstar Chain Drugstore in second quarter 2009 when compared to the same period in 2008

China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or "the Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the quarter ended June 30, 2009.

24 Aug 2009

Drugs News and Research

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Combined therapy for acute leukemia shows promising results

LAF report estimates the total economic burden of new cancer cases at $305 billion in 2009

New RAND study finds that Prescription Benefit Program for Medicare recipients surpasses expectations

Value-Based Insurance Design improves health care services

Impact Fusion International to commence filming of Anti-Steroids and Anti-Drug Campaign

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Myoderm expands its portfolio to include drug procurement, management and distribution services

Comparative effectiveness: Back surgery remains popular despite poor study results

Scientists cultivate multiple types of retina cells from human stem cells

UCLA finds link between high cholesterol and osteoporosis

Thick blood to cause or prevent strokes and heart attacks proved by scientists

Washington post examines spread of drug-resistant TB in Russia

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

ARIAD's petition for rehearing the Lilly NF-Kb patent lawsuit is granted by the Federal Circuit

Simcere to collaborate with Sun Yat-Sen University Cancer Center to research and develop anti-cancer drugs

Study reveals that increased neurostimulation market offers growth for device industries

PLoS Medicine's editors to eventually stamp ghostwriting

Gross profit declines for China Nepstar Chain Drugstore in second quarter 2009 when compared to the same period in 2008

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News